Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.54 |
| ▸ | FEN1 | P39748 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158705 | 0.98 | RAB9A (0.68) | RAB9AHTTMAPK1ALDH1A1ERCC5 | |
| SCHEMBL6320074 | 0.78 | ERCC5 (0.74) | RAB9AHTTMAPK1ALDH1A1ERCC5 | |
| SCHEMBL7070914 | 0.77 | ERCC5 (0.71) | RAB9AHTTMAPK1ALDH1A1ERCC5 | |
| SCHEMBL4748498 | 0.76 | ALDH1A1 (0.87) | RAB9AHTTMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL61103 | 0.76 | ALDH1A1 (0.87) | RAB9AHTTMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL28038078 | 0.76 | HTT (0.97) | RAB9AHTTALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9852558 | 0.75 | TRPV6 (0.55) | RAB9AHTTMAPK1ALDH1A1ERCC5 | |
| SCHEMBL27474866 | 0.75 | MAPK1 (0.61) | RAB9AHTTMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6510709 | 0.73 | ERCC5 (0.72) | RAB9AALDH1A1ERCC5FEN1SMN1; SMN2 | |
| SCHEMBL13093048 | 0.73 | ALDH1A1 (0.67) | HTTMAPK1ALDH1A1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293899-B2 | Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates | LANXESS DEUTSCHLAND GMBH (DE) | 2012-10-23 | — | — | US | disclosed |
| EP-1340746-B1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | SALTIGO GMBH (DE) | 2007-02-28 | — | — | EP | disclosed |
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | LANXESS DEUTSCHLAND GMBH (DE) | 2003-12-04 | — | — | US | disclosed |
| EP-1340746-A1 | Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives | BAYER AG (DE) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225274-A1 | Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives | GRHPR, HPD, HAAO | RAB9A 3428/4885HTT 1422/4885MAPK1 4183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.